FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

U.S. stocks appear poised for a positive opening on Friday, as strong earnings from major companies throughout the week have ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults ...

The Food and Drug Administration on Monday granted marketing approval to GlaxoSmithKline for Priorix, a vaccine to prevent measles, mumps and rubella in individuals a year or older.

As per the deal, GlaxoSmithKline will pay the vaccine maker up to $1.2 billion more if certain milestones are arrived at in Affinivax's impending clinical trials for a new pneumococcal vaccine.

GlaxoSmithKline has been called GSK for years — but the pharma company officially made the move to simplify the name this week. GlaxoSmithKline is now officially just GSK, the company announced Monday ...

GlaxoSmithKline is hunting for assets to build up its drug portfolio and the pharmaceutical giant is getting a big one through a $1.9 billion deal to acquire Sierra Oncology, a company whose lead ...